Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
1.400 Leser
Artikel bewerten:
(2)

EQS-Adhoc: Medacta Group SA: Publication of 2019 Annual Results

DJ EQS-Adhoc: Publication of 2019 Annual Results

EQS Group-Ad-hoc: Medacta Group SA / Key word(s): Annual Results 
Publication of 2019 Annual Results 
 
06-Apr-2020 / 07:00 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*Press Release - Publication of 2019 Annual Results * 
 
*Medacta achieves organic growth of 13.9% significantly above the market and 
strong profitability equal to 29.5% of Adjusted EBITDA margin[1].* 
 
*- Sales increased organically by 13.9% to EUR 310.6 million on a reported 
currency basis (11.3% on a constant currency basis) significantly above 
market. * 
 
*- Strong profitability, adjusted EBITDA increased to EUR 91.5 million, 
corresponding to an adjusted EBITDA margin of 29.5%. * 
 
*- Strong start into the 2020 financial year prior to the beginning of 
coronavirus crisis.* 
 
*- Countermeasures to limit the impact of the coronavirus taken swiftly. 
Facilities in Ticino/Switzerland remain operational to date.* 
 
*- Medacta has historically maintained a moderate net debt ratio. To protect 
its future cash flow and liquidity, the Board of Directors has proposed not 
to distribute a dividend for the financial year 2019.* 
 
*- Conscious of Covid-19 related uncertainties, Medacta withholds financial 
guidance for 2020. Mid and long-term fundamentals remain unchanged.* 
 
CASTEL SAN PIETRO, 6 April 2020 - Francesco Siccardi, CEO of Medacta, says 
"During these challenging times, our priority is to protect the health and 
safety of our employees, customers and patients. The Group Executive Team 
along with the Board of Directors are working very hard to assess and 
mitigate the risks and take actions to limit the financial impact of the 
pandemic on our business. 
We expect that orthopaedic patients will generate waiting lists in different 
markets and, depending on the duration of the deferral of elective 
surgeries, a recovery could start later in the year. Overall, we are 
confident that mid and long-term fundamentals have not changed and the 
encouraging growth we experienced in the first two months of the year will 
be back after the storm ends and the dust has settled". 
 
*Overview of 2019* 
Medacta Group SA (Medacta) continued to expand significantly faster than the 
orthopaedic market, achieving strong organic revenue growth and double-digit 
expansion. Total revenue increased by EUR 38.0 million, or 13.9%, from EUR 
272.6 million in 2018 to EUR 310.6 million in 2019 on a reported currency 
basis (11.3% on a constant currency basis). The increase was largely due to 
higher levels of market penetration in existing territories, which in turn 
led to increased sales volumes of the Hip, Knee, Spine and Shoulder product 
offerings. Higher levels of market penetration were supported by an expanded 
direct sales force, which grew through the addition of direct sales 
representatives and agents, strong Medical Education activities including 
the successful 9th M.O.R.E. International Symposium, which attracted about 
1'500 attendees from all over the world. 
 
KEY FINANCIAL FIGURES             31.12.2019   31.12.2018 
(Million Euro) 
Revenues                          310.6        272.6 
Gross Profit                      223.7        204.0 
Alternative Performance Measures: 
EBITDA                            53.3         86.3 
Adjusted EBITDA*                  91.5         87.9 
Adjusted EBITDA margin*           29.5%        32.3% 
Free Cash Flow                    0.6          17.2 
Adjusted Free Cash Flow**         22.3         33.2 
(Million Euro) 
Total Assets                      412.6        365.6 
Total Equity                      123.2        89.1 
Equity Ratio                      29.9%        24.4% 
Number of employees               1'101        973 
 
* Adjusted for IPO costs, one-time tax duty, Fidelity 
Bonus, provisions on litigations, extraordinary legal 
expenses, profit on sale of non-strategic asset. 
The reconciliation is provided in the "Alternative 
Performance Measures" section of the Management Report. 
IFRS 16 adoption starting from January 1, 2019 positively 
impacted our EBITDA, since lease expenses are classified 
in depreciation of right-of-use assets (Euro 2'964 
thousand) and financial costs (Euro 191 thousand). In the 
comparative period, lease expenses were classified within 
"Opex" for a total amount of Euro 2'990 thousand. 
** Please see the "Alternative Performance Measures" 
section of the Management Report for the reconciliation 
of the "Adjusted Free Cash Flow". IFRS 16 adoption 
starting from January 1, 2019 positively impacted our 
Free Cash Flow, since lease expenses are classified in 
depreciation of right-of-use assets (Euro 2'964 
thousand). In the comparative period, lease expenses were 
classified within the "Cash Flow from operating 
activities" for a total amount of Euro 2'990 thousand. 
 
*Growth in all business lines and regions* 
The core Joint product line contribution has been robust. The Hip line 
continued to develop, achieving sales growth of 5.2% at constant currency 
and reported sales of EUR 163.9 million, and benefit from the AMIS 
technique. In the Knee product line there was a strong growth of 13.2% at 
constant currency, with reported sales of EUR 111.7 million, sustained by an 
integrated proposal of innovative implants, personalized MIKA approach and 
GMK Single Use Instrumentation. The patient-matched and minimally invasive 
solution MySpine MIS MC have been the key elements of the positive results 
of the Spine product line, which showed a good acceleration in the second 
part of the year with an impressive 23.4% of revenue growth at constant 
currency and reported sales of EUR 25.3 million. Thanks to the comprehensive 
product portfolio and a successful deployment strategy, the Shoulder product 
line was able to reach 147.4% growth rate at constant currency and reported 
revenue of EUR 9.7 million. 
 
Medacta achieved balanced geographic sales growth in all key markets. Europe 
registered 7.9% growth rate at constant currency and reported sales of EUR 
136.1 million, primarily driven by Italy and Germany. North America market 
realized an overall good performance showing 13.2% growth rate at constant 
currency and reported revenue of EUR 95.5 million. The U.S. remains one of 
Medacta's strategic markets and a key focus for 2020. Asia-Pacific delivered 
the strongest result among all geographic areas, reaching 13.3% revenue 
growth at constant currency and EUR 66.9 million of reported revenue. This 
good result is attributable to a well-executed marketing strategy capable of 
generating noticeable acceleration mainly in the second part of the year. 
 
*High CORE Gross Profit margin of 73.0%* 
The CORE Gross Profit (adjusted for the Fidelity Bonus for employees) 
increased by 11.2%, from EUR 204.0 million in the previous year to EUR 226.9 
million in the reporting period.1 The CORE Gross Profit margin, equal to 
73.0%, decreased by 1.8% in comparison to the previous year. 1 This was 
primarily due to expected price reductions in certain European countries, 
higher raw material prices, higher royalties and incremental depreciation 
given the investments made on new instruments to sustain future growth, not 
sufficiently counterbalanced by positive effects on average selling prices 
deriving from revenue geographic mix and product mix. 
 
*Adjusted EBITDA surges to EUR 91.5 million* 
The Adjusted EBITDA amounted to EUR 91.5 million, 4.1% increase compared to 
a year ago. The adjustments, in the amount of EUR 38.2 million, include 
mainly one-time expenses associated with the IPO, Fidelity Bonus, 
extraordinary legal costs, stamp duty and accrued provisions on litigation.1 
The Adjusted EBITDA corresponds to a margin of 29.5%, compared to 32.3% in 
the previous year. The reduction in profitability was mainly due to the 
combined effect of expected increasing core business expenses and revenue 
growth rate slightly slower than expected. Higher costs were incurred 
particularly in association with the listing and the strengthening of 
corporate functions as well as in marketing and research activities. 
 
*Solid Balance Sheet* 
Medacta's Balance Sheet remains robust, with total assets of EUR 412.6 
million and an equity ratio of 29.9% at the end of the reporting period. The 
Adjusted Free Cash Flow generated in 2019 amounted to EUR 22.3 million after 
significant investments in new instruments and Research & Development to 
sustain the future growth of Medacta.1 
 
*Long-term value creation continues* 
The orthopaedics market is characterized by continuous technological 
changes, frequent new product introductions and evolving industry standards 
resulting from technological advances and scientific discoveries. In this 
complex environment, Medacta creates long-term value with its strategic 
focus on innovation, education and healthcare sustainability. Innovation is 
based on three pillars: complete and profound knowledge of the human body, 
continuous investments in long and short-term research and development (R&D) 
and adoption of cutting-edge technologies. Education is the indispensable 
tool to transforming innovation into concrete benefits for patients, 
surgeons and healthcare systems. As such, around 1'250 surgeons, on top of 
the 9th M.O.R.E. International Symposium, attended educational events and 
participated in more than 750 surgeon-to-surgeon visits in the year under 
review. As a result, Medacta's innovative products and surgical procedures 
improve patient well-being, facilitate the work of the customer surgeons and 
increase the sustainability of the healthcare system by improving efficiency 
while reducing surgical costs. 
 
*COVID-19 IMPACT * 
We are constantly monitoring the impact of the Covid-19 and how the pandemic 
is affecting our business. The health and safety of our employees, customers 
and patients are our number one priority and Medacta is working very hard to 
assess and mitigate any risks, taking all the actions needed to limit the 
impact of the pandemic. Over 270 Headquarters employees have been working 
remotely since March 9, and we have adopted all Government guidance and 
more, including social distancing, hand sanitizer, daily temperature 
measurement and masks, amongst others. As a MedTech company compliant with 
Government requirements, and thanks to the swiftly countermeasures taken by 
Management, our facilities in Ticino/Switzerland remain operational to date. 
 
From a business perspective, starting from March 2020 we have seen a severe 
reduction of elective surgeries in several countries, including Italy, 
Switzerland, France, Australia, and we anticipate more countries to follow. 
Marketing, Medical Education and other costs have been reduced substantially 
due to travel restrictions and we introduced cost containment measures, 
including short time work wherever appropriate. Also, we are using all the 
available Government support, in Switzerland and in all the markets in which 
Medacta operates with its subsidiaries, to offset labour costs whenever 
possible. 
 
To further protect our cash flow, the Board of Directors decided not to 
propose to the Annual General Meeting any distribution of dividend for the 
2019 financial year. 
 
*OUTLOOK 2020* 
Sales for the first two months of 2020 were very strong and in line with 
management expectations, recording constant currency growth in the low to 
mid-teens range. March was heavily affected by the Covid-19 impact, reducing 
constant currency growth rate for Q1 to low single digit. Given the 
uncertainties brought by the widespread outbreak of Covid-19 and the 
inability to forecast the future development, we are not in a position to 
provide a short-term outlook. However, we expect, orthopaedic patients will 
generate waiting lists in different countries and, depending on the duration 
of the deferral of elective surgeries, in several of Medacta's markets, a 
recovery could start later in 2020 and partially in 2021. Overall, we do not 
believe that mid or long-term fundamentals have changed. 
 
*Detailed reporting* 
Medacta's Annual Report 2019 can be downloaded via this link: 
https://www.medacta.com/EN/financial-reports [1] 
 
*Webcast today at 3:00 pm (CEST)* 
Medacta Group SA will present its Annual Results 2019 during a webcast today 
at 3:00 pm (CEST). The results call will be headed by Francesco Siccardi 
(CEO) and Corrado Farsetta (CFO). 
The conference will be held in English. 
 
Live-Link: https://webcasts.eqs.com/medacta20200406 [2] 
 
For participants to the conference call (slides only): 
https://webcasts.eqs.com/medacta20200406/no-audio [3] 
 
Dial-in numbers for conference call function only: 
Switzerland: +41 44 580 6522 
Germany: +49 692 0174 4220 
UK: +44 203 009 2470 
US: +1 877 423 0830 
 
Code PIN participants: 82985923# 
 
*Financial Calendar:* 
 
*- *19 May 2020 Annual General Meeting 
 
- 22 July 2020 Publication of 2020 Half-Year unaudited top-line figures 
 
- 7 September 2020 Half-year results 2020 
 
*Contact* 
Medacta Group SA 
Corrado Farsetta, CFO 
Phone: +41 91 696 60 60 
investor.relations@medacta.ch 
 
*About Medacta:* 
Medacta is an international company specializing in the design and 
production of innovative orthopaedic products and the development of 
accompanying surgical techniques for joint replacement, spine surgery, and 
sports medicine. Established in 1999 in Switzerland, Medacta's products and 
surgical techniques are characterized by innovation. Medacta is a pioneer in 
developing new offerings on the basis of minimally invasive surgical 
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") 
technique for hip replacements. Medacta has leveraged its orthopaedic 
expertise and comprehensive understanding of the human body to develop the 
sophisticated "_MySolutions_" technology, which offers surgeons highly 
personalized pre-operative planning and implant placement methodologies by 
creating advanced personalized kinematic models and 3D planning tools for 
use in hip, knee, shoulder and spine procedures. 
 
*Disclaimer * 
This press release has been prepared by Medacta Group SA ('Medacta' and 
together with its subsidiaries, 'we', 'us' or the 'Group'). The information 
contained in the press release does not purport to be comprehensive. Please 
refer to the Medacta 2019 Annual Report available on our website at 
https://www.medacta.com/EN/investors [4]. 
 
*Forward-looking information* 
This press release has been prepared by Medacta and includes forward-looking 
information and statements concerning the outlook for our business. These 
statements are based on current expectations, estimates and projections 
about the factors that may affect our future performance. These 
expectations, estimates and projections are generally identifiable by 
statements containing words such as 'expects,' 'believes,' 'estimates,' 
'targets,' 'plans,' 'outlook' or similar expressions. 
There are numerous risks and uncertainties, many of which are beyond our 
control, that could cause our actual results to differ materially from the 
forward-looking information and statements made in this press release. 
Currently, it is very difficult to provide a meaningful prediction on how 
the Swiss governmental action in response to the ongoing outbreak of a novel 
coronavirus disease (COVID-19) will affect the Medacta's operations and how 
long such measures will remain in place. The COVID-19 outbreak has caused, 
and may continue to cause, economic instability and a significant decrease 
of total economic output in the affected areas and globally. The impact of 
the COVID-19 outbreak on the general economic environment in the markets in 
which Medacta operates remain uncertain and could be significant. In 
addition, other important factors that could cause such differences include: 
changes in the global economic conditions and the economic conditions of the 
regions and markets in which the Group operates; changes in healthcare 
regulations (in particular with regard to medical devices); the development 
of our customer base; the competitive environment in which the Group 
operates; manufacturing or logistics disruptions; the impact of fluctuations 
in foreign exchange rates; and such other factors as may be discussed from 
time to time. Although we believe that our expectations reflected in any 
such forward-looking statement are based upon reasonable assumptions, we can 
give no assurance that those expectations will be achieved. 
 
*Alternative Performance Measures* 
This press release contains certain financial measures of historical 
performance that are not defined or specified by IFRS, such as "constant 
currency", "EBITDA", "Adjusted EBITDA" or "CORE EBITDA", "Free Cash Flow", 
"Adjusted Free Cash Flow", "Net Debt" and "Leverage". Reconciliation of 
these measures as well as "CORE" financial measures is provided in the 
"Alternative Performance Measures" (APM) section of our 2019 annual report. 
These Alternative Performance Measures (APM) should be regarded as 
complementary information to, and not as a substitute for, the IFRS 
beginning performance measures. For definitions of APM, together with 
reconciliations to the most directly reconcilable IFRS line items, please 
refer section headed "Alternative Performance Measures" of the 2019 annual 
report. 
The 2019 annual report is available at 
https://www.medacta.com/EN/financial-reports [1]. 
 
[1] Alternative Performance Measures: This press release contains certain 
financial measures of historical performance that are not defined or 
specified by IFRS, such as "constant currency", "EBITDA", "Adjusted EBITDA" 
or "CORE EBITDA", "Free Cash Flow", "Adjusted Free Cash Flow", "Net Debt" 
and "Leverage". Reconciliation of these measures as well as "CORE" financial 
measures is provided in the "Alternative Performance Measures" (APM) section 
of the 2019 annual report. These Alternative Performance Measures (APM) 
should be regarded as complementary information to, and not as a substitute 
for the IFRS beginning performance measures. For definitions of APM, 
together with reconciliations to the most directly reconcilable IFRS line 
items, please refer section headed "Alternative Performance Measures" of the 
2019 annual report. The 2019 annual report is available at 
https://www.medacta.com/EN/financial-reports 
 
End of ad hoc announcement 
Language:    English 
Company:     Medacta Group SA 
             Strada Regina 
             6874 Castel San Pietro 
             Switzerland 
Phone:       +41 91 696 6060 
E-mail:      info@medacta.ch, investor.relations@medacta.ch 
Internet:    www.medacta.com 
ISIN:        CH0468525222 
Listed:      SIX Swiss Exchange 
EQS News ID: 1015607 
 
End of Announcement EQS Group News Service 
 
1015607 06-Apr-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0a30b22293a337789f181fbc0219e21f&application_id=1015607&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=016cfc461c7aa1bf168df6d9bc755a3b&application_id=1015607&site_id=vwd&application_name=news 
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d7cd1c4129d25696486729cb2ea8368e&application_id=1015607&site_id=vwd&application_name=news 
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9121542be6bb5d87e93f108779d17bcc&application_id=1015607&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

April 06, 2020 01:00 ET (05:00 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2020 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.